OYST News and Press, Oyster Point Pharma Inc. From 03/24/22

OKYO Pharma is a UK based developer of next generation ocular therapeutics based on GPCR and MRGPR. The company plans direct Phase 2 trial of its lead candidate following a pre-IND meeting with FDA. The company has filed F-1 for an IPO of its ADSs. For further details see: ...

PRINCETON, N.J., March 17, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced tha...

PRINCETON, N.J., March 01, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced tha...

Oyster Point Pharma, Inc. (OYST) Q4 2021 Earnings Conference Call February 24, 2022 16:30 ET Company Participants Daniel Lochner - Chief Financial Officer Jeffrey Nau - President and Chief Executive Officer John Snisarenko - Chief Commercial Officer Conference Call Participants Ken Cacciatore...

The following slide deck was published by Oyster Point Pharma, Inc. in conjunction with this event. For further details see: Oyster Point Pharma (OYST) Investor Presentation - Slideshow

Image source: The Motley Fool. Oyster Point Pharma, Inc. (NASDAQ: OYST) Q4 2021 Earnings Call Feb 24, 2022 , 4:30 p.m. ET Operator Continue reading For further details see: Oyster Point Pharma, Inc. (OYST) Q4 2021 Earnings Call Transcript...

Oyster Point Pharma press release (NASDAQ:OYST): Q4 GAAP EPS of -$1.61 misses by $0.23. Revenue of $6.59M beats by $6.29M. As of December 31, 2021, cash, cash equivalents, and restricted cash were $193.4 million, compared to $184.2 million as of September 30, 2021. For further details ...

FDA Approved TYRVAYA™ (varenicline solution) Nasal Spray for the Treatment of the Signs and Symptoms of Dry Eye Disease on October 15, 2021 TYRVAYA Nasal Spray Net Product Revenue of $1.2 Million in Q4’21, plus $5.4 Million Recognized from Ji Xing Pharmaceutica...

One of the largest pharmacy benefit management (PBM) companies in the United States has added TYRVAYA (varenicline solution) Nasal Spray to National Preferred, Basic and High-Performance Formularies, effective February 19, 2022. FDA Approved TYRVAYA Nasal Spray for the Treatment o...

PRINCETON, N.J., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Oyster Point Pharma, Inc. (Nasdaq: OYST), a commercial-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class pharmaceutical therapies to treat ophthalmic diseases, today announced that...